All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APL-1501
Therapeutic Area: Oncology Product Name: APL-1501
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Australian regulatory authorities have approved company's Phase I clinical trial of APL-1501. APL-1202 is being developed as a new drug of Asieris for the treatment of non-muscle invasive bladder cancer (NMIBC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 28, 2020
Details:
Gracell’s lead FasTCAR autologous product candidate, GC012F, is being studied in an ongoing investigator-initiated Phase 1 trial in China for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its lead TruUCAR allogeneic product candidate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lemzoparlimab,Pembrolizumab,Rituximab
Therapeutic Area: Oncology Product Name: TJC4
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
Poster presentation highlights data from the U.S. phase 1 trial of lemzoparlimab, a highly differentiated anti-CD47 monoclonal antibody, for treatment of relapsed or refractory malignancy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-115
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Ascentage Pharma's APG-115 is a selective, small-molecule inhibitor of MDM2. is the first MDM2-p53 inhibitor entering clinical development in China and APG-1252 is novel drug that restores apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins simultaneously.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CNCT19
Therapeutic Area: Oncology Product Name: CNCT19
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CASI Pharmaceuticals
Deal Size: $10.4 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 29, 2020
Details:
With the restructuring in place, Juventas now can attract new capital to help fund its upcoming trials and build out a world-class GMP manufacturing facility for commercial production of CNCT19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): D-0502
Therapeutic Area: Oncology Product Name: D-0502
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: GL Ventures
Deal Size: $147.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing September 28, 2020
Details:
D-0502 is an oral selective estrogen receptor degrader (SERD), which also acts as an estrogen receptor antagonist, with therapeutic potential for the treatment of hormone receptor positive breast cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TAEST16001
Therapeutic Area: Oncology Product Name: TAEST16001
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: GenScript Biotech Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
As the first product in XLifeSc's pipeline, TAEST16001 enables autologous T-cell transduced with a replication incompetent lentiviral vector to express NY-ESO-1-specific TCR.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): oHSV-1
Therapeutic Area: Oncology Product Name: MVR-T3011
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Healthcare Capital
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 23, 2020
Details:
This investment further deepens ImmVira's collaboration in the MVR-T3011 intratumoral program and highlights the commitment from the parties to the program's commercial success.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lemzoparlimab
Therapeutic Area: Oncology Product Name: TJC4
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
Lemzoparlimab is a highly differentiated anti-CD47 monoclonal antibody originally discovered and developed by I-Mab. It is designed to minimize inherent binding to normal red blood cells while preserving its strong anti-tumor activity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZN-A-1041
Therapeutic Area: Oncology Product Name: ZN-A-1041
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
ZN-A-1041 is being developed to address the unmet medical need associated with brain metastases accompanying HER2+ advanced breast cancer.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
